Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GCGR | P47871 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28190516 | 0.89 | RAB9A (0.65) | RAB9APOLBIDO1ALOX15ADORA3 | |
| SCHEMBL20099873 | 0.84 | CYP3A4 (0.60) | RAB9APOLBIDO1ALOX15ADORA3 | |
| SCHEMBL20099830 | 0.83 | KMT2A (0.57) | RAB9APOLBGCGRMAPK14ALOX15 | |
| SCHEMBL20279023 | 0.83 | RAB9A (0.49) | RAB9APOLBALOX15ALDH1A1MAPT | |
| SCHEMBL20099768 | 0.83 | MEN1 (0.57) | RAB9APOLBALOX15MAPTHPGD | |
| SCHEMBL20099880 | 0.82 | RAB9A (0.45) | RAB9APOLBALOX15MAPTHPGD | |
| SCHEMBL20099884 | 0.82 | POLB (0.56) | RAB9APOLBALOX15ADORA3HPGDS | |
| SCHEMBL20099793 | 0.82 | POLB (0.56) | RAB9APOLBALOX15ADORA3HPGDS | |
| SCHEMBL27618709 | 0.81 | MAP4K1 (0.52) | RAB9APOLBIDO1ALOX15ADORA3 | |
| SCHEMBL17943298 | 0.81 | MEN1 (0.61) | RAB9APOLBALOX15ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287251-B2 | Pyrazole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2019-05-14 | — | — | US | disclosed |
| US-20180170879-A1 | PYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | US | disclosed |
| US-20180170879-A1 | PYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | US | disclosed |
| EP-3315492-A1 | PYRAZOLE DERIVATIVE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2018-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287251-B2 | Pyrazole derivative or pharmaceutically acceptable salt thereof | TRPM8, HCN3, HCN4 | RAB9A 508/4885POLB 4822/4885GCGR 2036/4885 |
| US-20180170879-A1 | PYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TRPM8, HCN3, HCN4 | RAB9A 387/4885POLB 4786/4885GCGR 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.